A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer.
OBJECTIVE
The enzyme matrix metalloproteinase (MMP)-1 is involved in ovarian carcinogenesis. A common guanine insertion-deletion promoter polymorphism within the gene encoding MMP-1 (MMP1) has been suggested to be a candidate gene for ovarian cancer. We investigated whether this common polymorphism can also serve as independent prognostic parameter in a large series of affected women.


METHODS
The MMP1 promoter polymorphism was examined in 151 Caucasian patients with epithelial ovarian cancer using polymerase chain reaction. Results were correlated with clinical data.


RESULTS
No associations were ascertained between the MMP1 polymorphism and tumor stage (P = 1.0, odds ratio [OR] 1.08), lymph node involvement (P = 1.0, OR 0.8), tumor grading (P = 0.2, OR 0.5), and patient's age at diagnosis (P = 1.0, OR 1.04). Besides the clinically established prognosticators, tumor stage and histological grade, presence of the MMP1 polymorphism was associated with a shortened disease-free and overall survival in a univariate Kaplan-Meier analysis (P = 0.01) and a multivariate Cox regression model (P = 0.04).


CONCLUSIONS
Presence of the MMP1 gene promoter polymorphisms was found to be a negative prognostic parameter in patients with ovarian cancer.
Six
Lucia
L
Department of Obstetrics and Gynecology, Molecular Oncology Group, Medical University of Vienna, A-1090 Vienna, Austria.
Grimm
Christoph
C
Leodolter
Sepp
S
Tempfer
Clemens
C
Zeillinger
Robert
R
Sliutz
Gerhard
G
Speiser
Paul
P
Reinthaller
Alexander
A
Hefler
Lukas A
LA
D005260:Female; D006801:Humans; D020781:Matrix Metalloproteinase 1 / Q000235:genetics*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology; D011110:Polymorphism, Genetic; D011379:Prognosis; D011401:Promoter Regions, Genetic
D020781:Matrix Metalloproteinase 1